The Netherlands pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
Dosing
Page 4 of 31 of this archive, newest first.
Tolerability is the ceiling, and the ceiling is personal
An effect is dose-limiting when it prevents adequate intake, prevents normal activity, or produces a risk of its own. Discomfort alone is not the test.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Forty-four per cent: reading the nausea figure properly
Severity in these tables is graded by interference with activity, not by how unpleasant the experience was. Those are different measurements.
What happens when the drug is taken away: three randomised answers
What was withdrawn, from whom, after how long, and what was measured afterwards.
Denmark pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The lowest effective dose is a real concept with almost no data behind it
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
Portugal pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
Continued treatment against continued placebo: the comparison that settled it
The regain trajectories, arm by arm, with the estimands named.
What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Antiemetics, laxatives and the thin literature underneath them
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.
Poland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
What we would need to measure to explain the response distribution
The mechanism is well described. The variance is not.
The mechanism behind the mechanism
Delayed gastric emptying is a mechanism that becomes an adverse effect above a threshold. It is not a complication in the ordinary sense.
The upper rungs, ranked by evidence
Where the curve flattens, what flattens with it, and what does not.
What a month without the drug does to tolerability
Concentrations fall by half a week, so a month away leaves a small fraction of steady state. Resuming at the previous dose presents the receptor with a step it has not seen…
Pancreatitis, obstruction, gallbladder: three things nausea can be
Rapid weight loss by any means raises gallstone risk. Separating that from a direct drug effect requires a comparator, and the trials have one.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Lipohypertrophy, and the absorption it ruins
Repeated injection into the same small area produces lipohypertrophy — thickened, rubbery subcutaneous tissue with blunted and erratic absorption. It is common, it is…
A design note on withdrawal trials, and why the run-in matters
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.